07 Oct 2026, 15:25 IST
Lupin Limited
HDFC Securities · ADD · target Rs 2,630
The report expects a 14% YoY EBITDA decline due to competition-led price erosion in Tolvaptan and gMyrbetriq, listing it as a muted performer.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.